ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

VTAE Vitae Pharmaceuticals, Inc. (MM)

20.99
0.00 (0.00%)
Mar 27 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 0
Bid Price 20.96
Ask Price 21.02
News -
Company Name Stock Ticker Symbol Market Type
Vitae Pharmaceuticals, Inc. (MM) VTAE NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.00% 20.99 20:00:00
Open Price Low Price High Price Close Price Prev Close
20.99 20.99
Trades Volume Avg Volume
0 0 -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 20.99 USD

Vitae Pharmaceuticals, Inc. (MM) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 605.37M - - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

VITAE PHARMACEUTICALS, INC News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No VTAE Message Board. Create One! See More Posts on VTAE Message Board See More Message Board Posts

Historical VTAE Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.00%
1 Month0.000.000.000.0000.000.00%
3 Months0.000.000.000.0000.000.00%
6 Months0.000.000.000.0000.000.00%
1 Year0.000.000.000.0000.000.00%
3 Years0.000.000.000.0000.000.00%
5 Years0.000.000.000.0000.000.00%

VITAE PHARMACEUTICALS, INC Description

Vitae Pharmaceuticals Inc was incorporated in Delaware in May 2001. The Company is a clinical stage biotechnology company focused on discovering and developing novel, small molecule drugs for diseases in which there are significant unmet medical needs. The Company is developing a robust and growing portfolio of novel product candidates internally generated by Contour, its proprietary structure-based drug discovery platform. The Company's product candidate include VTP-43742, a first in class oral small molecule, which is being developed for the treatment of psoriasis as well as multiple autoimmune disorders, and is currently being studied in a Phase 2a proof-of-concept clinical trial. The Company's other product candidate is VTP-38543 for the treatment of atopic dermatitis, which is in Phase 2a clinical development. The Company also has a product candidate, VTP-36951, in pre-clinical development for the treatment and prevention of Alzheimer's disease, or Alzheimer's.

Your Recent History

Delayed Upgrade Clock